Patents Assigned to NIPPON SHINYAKU CO.,
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180265866
    Abstract: The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
    Type: Application
    Filed: September 15, 2016
    Publication date: September 20, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
  • ANTISENSE NUCLEIC ACID FOR TREATING AMYOTROPHY
    Publication number: 20180251760
    Abstract: There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level. The present invention provides a specific antisense oligomer which allows exon 2 skipping in the myostatin gene or induces degradation of mRNA of the myostatin gene.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 6, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., Kawasaki Gakuen Educational Foundation
    Inventors: Shinichiro NAKAGAWA, Seigo NAGATA, Yoshihide SUNADA, Yutaka OHSAWA, Shin-ichiro NISHIMATSU
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180179538
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Application
    Filed: February 22, 2018
    Publication date: June 28, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Pyrazolothiazole compound and medicine comprising same
    Patent number: 9999622
    Abstract: The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: June 19, 2018
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventors: Yoshinobu Shiba, Satoshi Akiyama
  • Antisense nucleic acids
    Patent number: 9988629
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: June 5, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180142245
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Pyrazolothiazole compound and medicine comprising same
    Patent number: 9937176
    Abstract: The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: April 10, 2018
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventors: Yoshinobu Shiba, Satoshi Akiyama
  • PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME
    Publication number: 20180092919
    Abstract: The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 5, 2018
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventors: Yoshinobu Shiba, Satoshi Akiyama
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20180044675
    Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 15, 2018
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acids
    Patent number: 9890381
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: February 13, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
  • Antisense nucleic acids
    Patent number: 9840706
    Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 12, 2017
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Yuuichirou Tone, Shin'ichi Takeda, Tetsuya Nagata
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20170320903
    Abstract: The present invention provides a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
    Type: Application
    Filed: June 12, 2017
    Publication date: November 9, 2017
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
  • PYRAZOLOTHIAZOLE COMPOUND AND MEDICINE COMPRISING SAME
    Publication number: 20170252341
    Abstract: The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.
    Type: Application
    Filed: September 2, 2015
    Publication date: September 7, 2017
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventors: Yoshinobu SHIBA, Satoshi AKIYAMA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20170204410
    Abstract: Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.
    Type: Application
    Filed: June 16, 2015
    Publication date: July 20, 2017
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Antisense nucleic acids
    Patent number: 9708361
    Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: July 18, 2017
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS
    Publication number: 20170143722
    Abstract: The main purpose of the invention is to provide a novel aromatic heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include aromatic heterocyclic derivatives represented by general formula [1] and pharmaceutically acceptable salts thereof. In formula [1]: R1 represents phenyl optionally substituted with one or two groups selected from the group consisting of halogens, as well as alkyls and alkoxys optionally substituted by halogens; R2 represents hydrogen, an alkyl, cycloalkyl, or alkoxy optionally substituted by a halogen, or a heteroaryl optionally substituted by an alkyl; X represents CR3, and Y represents N or CR4, or X represents N, and Y represents CR4; and Z represents CR5 or N.
    Type: Application
    Filed: January 10, 2017
    Publication date: May 25, 2017
    Applicant: NIPPON SHINYAKU CO., LTD.
    Inventors: Katsutoshi HORI, Hiroki HAYASE, Tomohiro TERADA
  • ANTISENSE NUCLEIC ACIDS
    Publication number: 20170067052
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Application
    Filed: October 31, 2016
    Publication date: March 9, 2017
    Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
  • Substituted pyrrolidines as ROS tyrosine kinase inhibitors
    Patent number: 9580413
    Abstract: The main purpose of the invention is to provide a novel aromatic heterocyclic derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include aromatic heterocyclic derivatives represented by general formula [1] and pharmaceutically acceptable salts thereof. In formula [1]: R1 represents phenyl optionally substituted with one or two groups selected from the group consisting of halogens, as well as alkyls and alkoxys optionally substituted by halogens; R2 represents hydrogen, an alkyl, cycloalkyl, or alkoxy optionally substituted by a halogen, or a heteroaryl optionally substituted by an alkyl; X represents CR3, and Y represents N or CR4, or X represents N, and Y represents CR4; and Z represents CR5 or N.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: February 28, 2017
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventors: Katsutoshi Hori, Hiroki Hayase, Tomohiro Terada
  • Antisense nucleic acids
    Patent number: 9512424
    Abstract: The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: December 6, 2016
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
  • Fibrosis inhibitor
    Patent number: RE46364
    Abstract: [Object] The main object of the present invention is to provide a fibrosis inhibitor. [Solving Means] The present invention relates to a fibrosis inhibitor containing the heterocyclic derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient; In the formula (1), R1 and R2 are the same or different and each represents an optionally substituted aryl; R3 and R4 are the same or different and each represents hydrogen atom or alkyl; R5 represents hydrogen atom, alkyl or halogen atom; Y represents N or N?O; A represents NR6, and R6 represents hydrogen atom, alkyl, etc.; D represents alkylene or alkenylene which is optionally substituted with hydroxy; E represents phenylene or a single bond; G represents O, S, etc.; and Q represents carboxy, alkoxycarbonyl, etc.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 11, 2017
    Assignee: NIPPON SHINYAKU CO., LTD.
    Inventors: Koji Murakami, Takuya Toramoto